Use of pain at baseline and pain progression to predict overall survival (OS) in patients (pts) with docetaxel pretreated metastatic castration-refractory prostate cancer (CRPC): Results from the SPARC trial
Conferences
Sartor, AO; Petrylak, D; Sternberg, C; Witjes, F; Halabi, S; Berry, W; Petrone, M; McKearn, T; Noursalehi, M; George, M
Published in: JOURNAL OF CLINICAL ONCOLOGY
May 20, 2009
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
JOURNAL OF CLINICAL ONCOLOGY
ISSN
0732-183X
Publication Date
May 20, 2009
Volume
27
Issue
15
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Sartor, A. O., Petrylak, D., Sternberg, C., Witjes, F., Halabi, S., Berry, W., … George, M. (2009). Use of pain at baseline and pain progression to predict overall survival (OS) in patients (pts) with docetaxel pretreated metastatic castration-refractory prostate cancer (CRPC): Results from the SPARC trial. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 27).
Sartor, A. O., D. Petrylak, C. Sternberg, F. Witjes, S. Halabi, W. Berry, M. Petrone, T. McKearn, M. Noursalehi, and M. George. “Use of pain at baseline and pain progression to predict overall survival (OS) in patients (pts) with docetaxel pretreated metastatic castration-refractory prostate cancer (CRPC): Results from the SPARC trial.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 27, 2009.
Sartor AO, Petrylak D, Sternberg C, Witjes F, Halabi S, Berry W, et al. Use of pain at baseline and pain progression to predict overall survival (OS) in patients (pts) with docetaxel pretreated metastatic castration-refractory prostate cancer (CRPC): Results from the SPARC trial. In: JOURNAL OF CLINICAL ONCOLOGY. 2009.
Sartor, A. O., et al. “Use of pain at baseline and pain progression to predict overall survival (OS) in patients (pts) with docetaxel pretreated metastatic castration-refractory prostate cancer (CRPC): Results from the SPARC trial.” JOURNAL OF CLINICAL ONCOLOGY, vol. 27, no. 15, 2009.
Sartor AO, Petrylak D, Sternberg C, Witjes F, Halabi S, Berry W, Petrone M, McKearn T, Noursalehi M, George M. Use of pain at baseline and pain progression to predict overall survival (OS) in patients (pts) with docetaxel pretreated metastatic castration-refractory prostate cancer (CRPC): Results from the SPARC trial. JOURNAL OF CLINICAL ONCOLOGY. 2009.
Published In
JOURNAL OF CLINICAL ONCOLOGY
ISSN
0732-183X
Publication Date
May 20, 2009
Volume
27
Issue
15
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis